Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial

Ning Li, MD; Jianqing Zhu, MD; Rutie Yin, MD; et al.

JAMA Oncol. 2023;9(9):1230-1237. doi:10.1001/jamaoncol.2023.2283

Conclusion

Niraparib maintenance therapy prolonged PFS in patients with newly diagnosed aOC regardless of postoperative residual disease or biomarker status. The ISD was effective and safe in the first-line maintenance setting.